[go: up one dir, main page]

MX2018004517A - Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-i l]nicotinonitrilo y su uso como inhibidores de cinasas asociadas al receptor de interleucina-1 (irak). - Google Patents

Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-i l]nicotinonitrilo y su uso como inhibidores de cinasas asociadas al receptor de interleucina-1 (irak).

Info

Publication number
MX2018004517A
MX2018004517A MX2018004517A MX2018004517A MX2018004517A MX 2018004517 A MX2018004517 A MX 2018004517A MX 2018004517 A MX2018004517 A MX 2018004517A MX 2018004517 A MX2018004517 A MX 2018004517A MX 2018004517 A MX2018004517 A MX 2018004517A
Authority
MX
Mexico
Prior art keywords
ethoxyethoxy
imidazo
pyridin
derivatives
amino
Prior art date
Application number
MX2018004517A
Other languages
English (en)
Inventor
Jeanne Marie Menet Christel
Christophe Xavier Brys Reginald
Mammoliti Oscar
Emiel Van Der Plas Steven
Georges Pierre- Olivier DOYON Julien
Jean Joël Geney Raphaël
Marie Joncour Agnès
Michel Lefrancois Jean-
Antoine Schmitt Benoît
Gilbert Labéguère Frédéric
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MX2018004517A publication Critical patent/MX2018004517A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe compuestos de acuerdo con la Fórmula I: (ver Fórmula) en donde R1, R2, y Cy son como se definen en el presente documento. La presente invención se refiere a compuestos que inhiben las cinasas de la familia IRAK, métodos para su producción, composiciones farmacéuticas que comprenden los mismos, y métodos de tratamiento que utilizan los mismos, para la profilaxis y/o tratamiento de enfermedades inflamatorias, enfermedades autoinmunes y/o enfermedades proliferativas mediante la administración del compuesto de la invención.
MX2018004517A 2015-10-19 2016-10-14 Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-i l]nicotinonitrilo y su uso como inhibidores de cinasas asociadas al receptor de interleucina-1 (irak). MX2018004517A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1518456.7A GB201518456D0 (en) 2015-10-19 2015-10-19 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
PCT/EP2016/074662 WO2017067848A1 (en) 2015-10-19 2016-10-14 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors

Publications (1)

Publication Number Publication Date
MX2018004517A true MX2018004517A (es) 2018-06-27

Family

ID=55131239

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004517A MX2018004517A (es) 2015-10-19 2016-10-14 Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-i l]nicotinonitrilo y su uso como inhibidores de cinasas asociadas al receptor de interleucina-1 (irak).

Country Status (18)

Country Link
US (1) US10508111B2 (es)
EP (1) EP3365341B1 (es)
JP (1) JP2018530617A (es)
KR (1) KR20180064528A (es)
CN (1) CN108137584A (es)
AR (1) AR106384A1 (es)
AU (1) AU2016343225A1 (es)
BR (1) BR112018007392A2 (es)
CA (1) CA3002255A1 (es)
CO (1) CO2018004765A2 (es)
GB (1) GB201518456D0 (es)
IL (1) IL258707A (es)
MX (1) MX2018004517A (es)
PH (1) PH12018500827A1 (es)
RU (1) RU2018117499A (es)
SG (1) SG11201803095UA (es)
TW (1) TW201718582A (es)
WO (1) WO2017067848A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
GB201702603D0 (en) * 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
GB201904373D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28506A1 (es) * 2003-09-12 2005-04-29 Basf Ag 6-halógeno-(1,2,4)triazolo(1,5-a)pirimidinas para combatir plagas animales.
KR101164541B1 (ko) * 2004-01-12 2012-07-10 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 선택적 키나제 저해제
BR112013020329A2 (pt) * 2011-02-09 2016-08-02 Hoffmann La Roche compostos heterocíclicos como inibidores da pi3-quinase
CN106232122A (zh) * 2013-09-27 2016-12-14 林伯士艾瑞斯公司 Irak抑制剂和其用途
TW201609693A (zh) * 2014-01-03 2016-03-16 必治妥美雅史谷比公司 雜芳基取代之菸鹼醯胺化合物

Also Published As

Publication number Publication date
CO2018004765A2 (es) 2018-07-19
EP3365341A1 (en) 2018-08-29
GB201518456D0 (en) 2015-12-02
TW201718582A (zh) 2017-06-01
RU2018117499A (ru) 2019-11-21
AR106384A1 (es) 2018-01-10
IL258707A (en) 2018-06-28
US20180305351A1 (en) 2018-10-25
AU2016343225A1 (en) 2018-05-10
CA3002255A1 (en) 2017-04-27
JP2018530617A (ja) 2018-10-18
WO2017067848A1 (en) 2017-04-27
EP3365341B1 (en) 2020-05-13
KR20180064528A (ko) 2018-06-14
CN108137584A (zh) 2018-06-08
US10508111B2 (en) 2019-12-17
PH12018500827A1 (en) 2018-10-29
BR112018007392A2 (pt) 2018-10-16
SG11201803095UA (en) 2018-05-30
RU2018117499A3 (es) 2020-01-24

Similar Documents

Publication Publication Date Title
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
PH12017501921A1 (en) Novel compounds
PH12017502050A1 (en) Naphthyridine compounds as jak kinase inhibitors
JOP20190143A1 (ar) مثبطات جزيئات صغيرة من عائلة jak لإنزيمات الكيناز
MX370390B (es) Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados.
MX2015014234A (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
MY194002A (en) 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
NZ749911A (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
PH12018500827A1 (en) 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors
ZA202105353B (en) Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
TR201907590T4 (tr) Ssao inhibitörleri olarak imidazo[4,5-c]piridin ve pirrolo[2,3-c]piridin türevleri.
WO2016010869A3 (en) FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
PH12017500007A1 (en) Quinolizinone derivatives as p13k inhibitors
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
HK1252245A1 (zh) 用於治疗癌症的核苷酸
EA032654B9 (ru) [1,2,4]ТРИАЗОЛО[4,3-b]ПИРИДАЗИНЫ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
NZ740119A (en) Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide
PH12015502746A1 (en) Prodrug derivatives of substituted triazolopyridines
MX2018004879A (es) Nuevos derivados de piridona y su uso como inhibidores de quinasas.
MX2016002078A (es) Derivados de 1h-pirazolo[3,4]piridina y composiciones farmaceuticas de los mismos para el tratamiento de trastornos proliferativos.
MY192305A (en) Bipyrazole derivatives as jak inhibitors
MY193381A (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
HK1228399A1 (en) Protein kinase inhibitors